Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the US Page 1

• Novavax expects prefilled syringes to be widely available at thousands of locations in the U.S.
• The Novavax vaccine is the only protein-based option available in the US for use in people 12 years and older to prevent COVID-19

GAITHERSBURG, Maryland., August 30, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company developing protein-based vaccines using its Matrix-M adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formulation) (NVX-CoV2705) has received Emergency Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals 12 years of age and older. Novavax’s vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on June 27, 2024.

Prefilled syringes of the vaccine will be available in thousands of locations, including pharmacies, independent pharmacies and regional grocery stores, after the Center for Biologics Evaluation and Research releases the vaccine batches.